Page 1395 - Williams Hematology ( PDFDrive )

1370 Part X: Malignant Myeloid Diseases Chapter 87: Myelodysplastic Syndromes 1371

459. Raza A, Reeves JA, Feldman EJ, et al: Phase 2 study of lenalidomide in transfusion-de- 488. Gunby RH, Cazzaniga G, Tassi E, et al: Sensitivity to imatinib but low frequency of the
pendent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia. Haematologica
other than deletion 5q. Blood 111(1):86–93, 2008. 88(4):408–415, 2003.
460. Fehniger TA, Byrd JC, Marcucci G, et al: Single-agent lenalidomide induces com- 489. Raza A, Galili N, Smith S, et al: Phase 1 multicenter dose-escalation study of ezatiostat
plete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with
113(5):1002–1005, 2009. myelodysplastic syndrome. Blood 113(26):6533–6540, 2009.
461. Deeg HJ, Gotlib J, Beckham C, et al: Soluble TNF receptor fusion protein (etanercept) 490. Raza A, Galili N, Mulford D, et al: Phase 1 dose-ranging study of ezatiostat hydro-
for the treatment of myelodysplastic syndrome: A pilot study. Leukemia 16(2):162–164, chloride in combination with lenalidomide in patients with non-deletion (5q) low to
2002. intermediate-1 risk myelodysplastic syndrome (MDS). J Hematol Oncol 5:18, 2012.
462. Rosenfeld C, Bedell C: Pilot study of recombinant human soluble tumor necrosis fac- 491. Raza A, Galili N, Callander N, et al: Phase 1–2a multicenter dose-escalation study of
tor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome. Leuk Res ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathi-
26(8):721–724, 2002. one analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol 2:20,
463. Maciejewski JP, Risitano AM, Sloand EM, et al: A pilot study of the recombinant soluble 2009.
human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myel- 492. Leone G, Teofili L, Voso MT, Lubbert M: DNA methylation and demethylating drugs
odysplastic syndrome. Br J Haematol 117(1):119–126, 2002. in myelodysplastic syndromes and secondary leukemias. Haematologica 87(12):
464. Stasi R, Amadori S: Infliximab chimaeric anti-tumour necrosis factor alpha monoclo- 1324–1341, 2002.
nal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol 493. Quesnel B, Fenaux P: P15INK4b gene methylation and myelodysplastic syndromes.
116(2):334–337, 2002. Leuk Lymphoma 35(5–6):437–443, 1999.
465. Scott BL, Ramakrishnan A, Fosdal M, et al: Anti-thymocyte globulin plus etanercept 494. Silverman LR: Targeting hypomethylation of DNA to achieve cellular differentiation in
as therapy for myelodysplastic syndromes (MDS): A phase II study. Br J Haematol myelodysplastic syndromes (MDS). Oncologist 6 (Suppl 5):8–14, 2001.
149(5):706–710, 2010. 495. Saunthararajah Y, Hillery CA, Lavelle D, et al: Effects of 5-aza-2′-deoxycytidine on fetal
466. Scott BL, Ramakrishnan A, Storer B, et al: Prolonged responses in patients with MDS hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with
and CMML treated with azacitidine and etanercept. Br J Haematol 148(6):944–947, sickle cell disease. Blood 102(12):3865–3870, 2003.
2010. 496. Goodyear OC, Dennis M, Jilani NY, et al: Azacitidine augments expansion of regu-
467. Yaguchi M, Miyazawa K, Katagiri T, et al: Vitamin K2 and its derivatives induce latory T cells after allogeneic stem cell transplantation in patients with acute myeloid
apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid. Leukemia leukemia (AML). Blood 119(14):3361–3369, 2012.
11(6):779–787, 1997. 497. de Vos D: Epigenetic drugs: A longstanding story. Semin Oncol 32(5):437–442, 2005.
468. Takami A, Nakao S, Ontachi Y, et al: Successful therapy of myelodysplastic syndrome 498. Palii SS, Van Emburgh BO, Sankpal UT, et al: DNA methylation inhibitor 5-Aza-2′-deox-
with menatetrenone, a vitamin K2 analog. Int J Hematol 69(1):24–26, 1999. ycytidine induces reversible genome-wide DNA damage that is distinctly influenced by
469. Nagler A, Rikilis I, Tatarsky I, Fabian I: Effect of 1,25-dihydroxyvitamin D3 and 13-cis- DNA methyltransferases 1 and 3B. Mol Cell Biol 28(2):752–771, 2008.
-retinoic acid on in vitro hematopoiesis in the myelodysplastic syndromes. J Lab Clin 499. Fabre C, Grosjean J, Tailler M, et al: A novel effect of DNA methyltransferase and his-
Med 110(2):237–244, 1987. tone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle
470. Rowinsky EK, Conley BA, Jones RJ, et al: Hexamethylene bisacetamide in myelodys- 7(14):2139–2145, 2008.
plastic syndrome: Effect of five-day exposure to maximal therapeutic concentrations. 500. Itzykson R, Fenaux P: Optimizing hypomethylating agents in myelodysplastic syn-
Leukemia 6(6):526–534, 1992. dromes. Curr Opin Hematol 19(2):65–70, 2012.
471. Tefferi A, Elliott MA, Steensma DP, et al: Amifostine alone and in combination with 501. Baer MR, Gojo I: Novel agents for the treatment of acute myeloid leukemia in the older
erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res patient. J Natl Compr Canc Netw 9(3):331–335, 2011.
25(2):183–185, 2001. 502. Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol
472. Raza A, Qawi H, Lisak L, et al: Patients with myelodysplastic syndromes benefit from 20(6):705–710, 2008.
palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without 503. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azaciti-
dexamethasone. Blood 95(5):1580–1587, 2000. dine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia
473. Jantunen E, Ruutu P, Niskanen L, et al: Incidence and risk factors for invasive fungal group B. J Clin Oncol 20(10):2429–2440, 2002.
infections in allogeneic BMT recipients. Bone Marrow Transplant 19(8):801–808, 1997. 504. Silverman LR, McKenzie DR, Peterson BL, et al: Further analysis of trials with azaciti-
474. Hast R, Axdorph S, Lauren L, Reizenstein P: Absent clinical effects of retinoic acid and dine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the
isoretinoin treatment in the myelodysplastic syndrome. Hematol Oncol 7(4):297–301, Cancer and Leukemia Group B. J Clin Oncol 24(24):3895–3903, 2006.
1989. 505. Silverman LR, Fenaux P, Mufti GJ, et al: The effects of continued azacitidine treatment
475. Ohno R, Naoe T, Hirano M, et al: Treatment of myelodysplastic syndromes with all- cycles on response in higher risk patients with myelodysplastic syndromes: An update.
trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. Blood Ecancermedicalscience 2:118, 2008.
81(5):1152–1154, 1993. 506. Gryn J, Zeigler ZR, Shadduck RK, et al: Treatment of myelodysplastic syndromes with
476. List A, Beran M, DiPersio J, et al: Opportunities for Trisenox (arsenic trioxide) in the 5-azacytidine. Leuk Res 26(10):893–897, 2002.
treatment of myelodysplastic syndromes. Leukemia 17(8):1499–1507, 2003. 507. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Efficacy of azacitidine compared with
477. Sekeres MA, Maciejewski JP, Erba HP, et al: A Phase 2 study of combination therapy that of conventional care regimens in the treatment of higher-risk myelodysplastic
with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 10(3):223–232,
syndromes or secondary acute myeloid leukemia. Cancer 117(6):1253–1261, 2011. 2009.
478. Bejanyan N, Tiu RV, Raza A, et al: A phase 2 trial of combination therapy with thalid- 508. Sekeres MA, Maciejewski JP, Donley DW, et al: A study comparing dosing regimens
omide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with and efficacy of subcutaneous to intravenous azacitidine (AZA) for the treatment of
overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary mye- myelodysplastic syndromes (MDS). ASH Annu Meet Abstr 114(22):3797, 2009.
lofibrosis (PMF). Cancer 118(16):3968–3976, 2011. 509. Garcia-Manero G, Stoltz ML, Ward MR, et al: A pilot pharmacokinetic study of oral
479. Schiller GJ, Slack J, Hainsworth JD, et al: Phase II multicenter study of arsenic trioxide azacitidine. Leukemia 22(9):1680–1684, 2008.
in patients with myelodysplastic syndromes. J Clin Oncol 24(16):2456–2464, 2006. 510. Lyons RM, Cosgriff TM, Modi SS, et al: Hematologic response to three alternative dos-
480. Terpos E, Verrou E, Banti A, et al: Bortezomib is an effective agent for MDS/MPD ing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol
syndrome with 5q– anomaly and thrombocytosis. Leuk Res 31(4):559–562, 2007. 27(11):1850–1856, 2009.
481. Braun T, Carvalho G, Coquelle A, et al: NF-kappaB constitutes a potential therapeutic 511. Platzbecker U, Aul C, Ehninger G, Giagounidis A: Reduction of 5-azacitidine induced
target in high-risk myelodysplastic syndrome. Blood 107(3):1156–1165, 2006. skin reactions in MDS patients with evening primrose oil. Ann Hematol 89(4):427–428,
482. Attar EC, Amrein PC, Fraser JW, et al: Phase I dose escalation study of bortezomib 2010.
in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) 512. Qin T, Castoro R, El Ahdab S, et al: Mechanisms of resistance to decitabine in the mye-
and acute myeloid leukemia (AML). Leuk Res 37(9):1016–1020, 2013. lodysplastic syndrome. PLoS One 6(8):e23372, 2011.
483. Maeda Y, Yamaguchi T, Hijikata Y, et al: Possible molecular target therapy with rapamy- 513. Steensma DP, Baer MR, Slack JL, et al: Multicenter study of decitabine administered
cin in MDS. Leuk Lymphoma 47(5):907–911, 2006. daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative
484. Follo MY, Mongiorgi S, Bosi C, et al: The Akt/mammalian target of rapamycin signal dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27(23):3842–3848, 2009.
transduction pathway is activated in high-risk myelodysplastic syndromes and influ- 514. Kantarjian H, Issa JP, Rosenfeld CS, et al: Decitabine improves patient outcomes in
ences cell survival and proliferation. Cancer Res 67(9):4287–4294, 2007. myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106(8):
485. Carrancio S, Markovics J, Wong P, et al: An activin receptor IIA ligand trap promotes 1794–1803, 2006.
erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J 515. Lubbert M, Wijermans P, Kunzmann R, et al: Cytogenetic responses in high-risk myel-
Haematol 165(6):870–882, 2014. odysplastic syndrome following low-dose treatment with the DNA methylation inhibi-
486. Bachegowda L, Gligich O, Mantzaris I, et al: Signal transduction inhibitors in treatment tor 5-aza-2′-deoxycytidine. Br J Haematol 114(2):349–357, 2001.
of myelodysplastic syndromes. J Hematol Oncol 6:50, 2013. 516. Kantarjian H, Oki Y, Garcia-Manero G, et al: Results of a randomized study of 3 sched-
487. Cortes J, Giles F, O’Brien S, et al: Results of imatinib mesylate therapy in patients with ules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic mye-
refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, lomonocytic leukemia. Blood 109(1):52–57, 2007.
and myeloproliferative disorders. Cancer 97(11):2760–2766, 2003.

Kaushansky_chapter 87_p1341-1372.indd 1370 9/21/15 11:06 AM